Arthrogen B.V.
|
Arthrogen B.V. Employees in Amsterdam: 10 |
Company Profile
Arthrogen was founded in 2005 as a joint venture of the Academic Medical Center (AMC, Amsterdam, The Netherlands) and the Dubai Bones and Joints Hospital for the clinical and commercial development of an innovative gene therapy approach, developed by researchers of the AMC, as a cure for rheumatoid arthritis locally in the joints. The lead compound will enter phase-I trials in two years.
Science and Technologies or Services
Development of local gene therapy targeting TNF might provide a novel method to treat isolated arthritis activity. This could lead to the development of novel therapeutic strategies targeting primarily the site of inflammation and prevent joint destruction. The gene delivery approach, in addition to other therapeutics, may ultimately provide a more comprehensive treatment for the management of RA. Obviously, achievement of this goal will have a substantial beneficial effect on the RA patient and ultimately on society. Arthrogen aims to develop several innovative medical strategies using gene therapy for local treatment of RA, using several types of cytokines.
Alliances
- Dubai Bones and Joints Center
- Academisch Medisch Centrum Amsterdam
- Galapagos BV
- Agendia BV
Keywords
- Rheumatoid arthritis
- Gene therapy
- Local administration
- Cytokines
